TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of ONC201 in Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
1. Subjects must have a unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine tumor including pheochromocytoma-paraganglioma (PC-PG), DSRCT, Ewing Sarcoma or PNET, or any neuroendocrine tumor with a catecholamine or dopamine biomarker or autocrine or paracrine dependence on dopamine including cholangiocarcinoma and adrenal cortical carcinoma (ACC).~2. There is no limit on number of prior therapies.~3. Age ≥14 years.~4. Subjects must have normal organ and marrow function as defined below. Studies should be done within 3 weeks prior to enrollment~   * Hemoglobin ≥ 10.0 g/dl~  * Leukocytes ≥ 1500/mcL~  * Absolute neutrophil count ≥ 1,000/mcL~  * Platelet count ≥ 75000/mcL~  * Total bilirubin within 1.5 x normal institutional limits~  * AST (SGOT) ≤ 5 X institutional upper limit of normal~  * ALT (SGPT) ≤ 5 X institutional upper limit of normal~  * Serum Creatinine \<3.0mg/dL~     * 5 1 lesion detectable on CT, MRI, 18FDG PET-CT~6 Subjects must have the ability to understand and the willingness to sign a written informed consent document.~7: Karnofsky or if \<16 years old Lansky Play Performance status ≥ 60%

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Metastatic PC-PG (Type: EXPERIMENTAL): 625mg ONC201 will be given once weekly
- Arm B: Other NETs (Type: EXPERIMENTAL): 625mg ONC201 will be given once weekly
- Arm C: PC-PG + other NETs (Type: EXPERIMENTAL): 625mg ONC201 will be given on day 1 and day 2 of each week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Treatments Following Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral TKR 2 to 4 months prior~* Older than 60 years of age~* Experience functional limitation in daily activities (score in WOMAC-PF of at least 9 points)~* Speak sufficient English to understand study instructions~* Have medical clearance to participate in the study~* Are willing to be randomized to one of the 3 treatment arms~Exclusion Criteria:~* Have absolute or relative contraindications to exercise~* Have history of uncontrolled cardiovascular disease or hypertension~* Are unable to walk 50 meters without an assistive device~* Have history of muscular or neurological disorder that affect lower extremity function~* Regular participation in exercise~* Terminal illness~* Planning to have another joint replacement during the next 12 months~* Plan not to be around during the next 12 months

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clinic-based outpatient exercise group (Type: EXPERIMENTAL): Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
- Community-based exercise group (Type: ACTIVE_COMPARATOR): Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
- Wait-listed usual medical care (Type: NO_INTERVENTION): Wait-listed usual medical care - no intervention provided by study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing multiple sclerosis (RMS) (McDonald Criteria 2010)~* Active disease~* Expanded disability status scale (EDSS) 0 - 5.5 (inclusive) at screening~Exclusion Criteria:~* Treatment with prior Anti-cluster of differentiate 20 (CD20) or other B cell directed treatment~* Treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and Stem cell transplantation~* Diagnosed with primary progressive multiple sclerosis (PPMS)~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ublituximab + Oral Placebo (Type: EXPERIMENTAL): Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
- Teriflunomide + IV Placebo (Type: ACTIVE_COMPARATOR): Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 sero-positive~* Aged 20 years or older~* Have received HAART treatment~* CD4+ T cell count ≧ 350 cells/mm3~* HIV-1 plasma RNA level remains below the limit of~* Were not breastfeeding for women~* Subjects with a negative serum pregnancy test result at screening visit for women of childbearing potential~* Subjects agree on using birth control barrier (female or male condom) during the entire study period~* Subjects sign the informed consent before undergoing any study procedures~Exclusion Criteria:~* Any active infection except for HIV, and required immediate therapy~* Any active AIDS-defining illness per Category B and Category C conditions according to the U.S. Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection~* Any documented CD4+ T cell count \< 200 cells/mm3 within the past 12 weeks before screening visit~* Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history, and/or physical examination that, in the investigator's opinion, would preclude the subject from participating in this study~* Any vaccination within 8 weeks prior to the first dose of study drug~* Any immunomodulating therapy (including interferon and steroid) or systemic chemotherapy within 12 weeks prior to the first dose of study drug~* Any illicit intravenous drugs within 12 weeks prior to the first dose of study drug~* Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the subject's ability to comply with the dosing, visit schedules and protocol evaluations~* More than one change of HAART regimen because of virologic failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cohort 1 (Type: EXPERIMENTAL): Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
- cohort 2 (Type: EXPERIMENTAL): Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients meeting the following criteria will be eligible for participation in th is study:~1. Human Immunodeficiency virus 1 (HIV-1) infected males or females \>=18 years of age.~2. Screening genotypic resistance report indicating both of the following: at least one primary protease Inhibitor (PI) mutation at the following sites:~30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on codons 33, 82, 84, or 90.~3. At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV) medication regimen for at least 3 months prior to randomization.~4. Human Immunodeficiency Virus 1 (HIV-1) viral load \>=1,000 copies/mL at screening.~Exclusion criteria:~Patients with any of the following criteria are excluded from participation in t he study:~1. Antiretroviral (ARV) medication naïve.~2. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the last 3 months.~3. alanine aminotransferase (ALT) \>=3.0x upper limit of normal (ULN) and aspartate aminotransferase(AST) \>=2.5x upper limit of normal (ULN) (\>=Division of AIDS(DAIDS) Grade 1) at either screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tipranavir(TPV)/low dose ritonavir(r) (Type: OTHER): None
- Comparator protease inhibitor(CPI)/low dose ritonavir(r) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging of the Effect of Music Listening on Brain Activity Under Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist physical status of 1 (ASA-1), Healthy, non-smoking, no or minimal alcohol use~* Right-handed~* Body mass index (BMI) of less than 30~* English speakers~Exclusion Criteria:~* Medical contraindication to Magnetic Resonance Imaging (MRI) scanning~* Unable to undergo MRI scanning because of possible pregnancy~* BMI over 30~* Tattoos in the head or neck region~* Unwilling to abstain from alcohol for 24 hours prior to dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Functional Magnetic Resonance Imaging (Type: EXPERIMENTAL): While music is played Noninvasive functional magnetic resonance (fMRI) imaging will be performed at the University of Michigan Health System, University Hospital, Department of Radiology.~The fMRI is done under anesthesia using propofol. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations of 1.2, 1.6, 2.0, and 2.4 μg/ml in a stepwise fashion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Italian citizens, residing in the Region~* Registered as beneficiaries for at least one year between January 1st, 2012 and September 30th, 2018~* Diagnosis of type 2 diabetes~* Newly initiating SGLT-2 inhibitors or GLP-1 receptor agonists~* Being treated with glucose lowering medications before (at least one prescription of an antidiabetic agent in ATC class A10B prior to the index date)~* Time between the index date and the last SGLT2 inhibitors or GLP-1 receptor agonists prescription shorter than 8 months,~* Follow-up time or time-to-endpoint of at least three months~Exclusion Criteria:~* Patients who started SGLT2i or GLP-1RA before 2014~* Patients with an insufficient exposure time~* Patients with an incident event within three months after the index date.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: None

Study Arms:
- SGLT2i (Type: None): Patients who received new prescription of a SGLT-2 inhibitor
- GLP-1RA (Type: None): Patients who received new prescription of a GLP-1 receptor agonist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age or older admitted for hospitalization from the community or a nursing home with CAP.~2. CAP will be defined by a new infiltrate on chest radiograph and the presence of one or several of the following acute respiratory signs or symptoms:~   * cough~  * sputum production~  * dyspnea~  * core body temperature \>38.0° C~  * auscultatory findings of abnormal breath sounds and rales~  * leukocyte count \>10 or \<4 x 109 cells L-1 (1)~Exclusion Criteria:~1. Patients or family members unable to give written informed consent, e.g. with severe dementia.~2. Patients with active intravenous drug use.~3. Severe immunosuppression (e.g. patients infected with human immunodeficiency virus infection and a CD4 count below 350 x 109/L, patients on immunosuppressive therapy after solid organ transplantation and neutropenic patients with neutrophil count \< 500 x 109/L and patients under chemotherapy with neutrophils 500-1000 x 109/L with an expected decrease to values \< 500 x 109/L); patients with cystic fibrosis as well as patients with active tuberculosis.~4. Patients with acute burn injury~5. Patients with acute gastrointestinal bleeding within 3 months of the current hospitalization~6. Patients with an acute concomitant condition requiring more than 0.5mg/kg/d prednisone equivalent~7. Pregnancy or breast feeding~8. Patients with known adrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone (Type: ACTIVE_COMPARATOR): Drug
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fetal ST Segment and T Wave Analysis in Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton, cephalic pregnancy~* Gestational age at least 36 weeks, 1 day~* Cervical dilation of at least 2 cm and no more than 7 cm~* Ruptured membranes~Exclusion Criteria:~* Multifetal gestation~* Planned cesarean delivery~* Need for immediate delivery~* Absent variability or sinusoidal pattern at any time, or a Category II fetal heart rate pattern with absent variability in the last 20 minutes before randomization~* Inability to obtain or maintain an adequate signal within 3 trials of electrode placements~* Occurrence of any ST event during attempt to obtain adequate signal~* Patient pushing in the first stage of labor~* Known major fetal anomaly or fetal demise~* Previous uterine surgery~* Placenta previa on admission~* Maternal fever greater than or equal to 38 C or 100.4 F~* Active HSV infection~* Known HIV or hepatitis infection~* Other maternal and fetal contraindications for using the STAN monitor~* Enrollment in another labor study~* Participation in this trial in a previous pregnancy~* No certified or authorized provider available

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Open Group (Type: EXPERIMENTAL): • Fetal STAN monitor electrode inserted and data available to caregivers
- Masked Group (Type: OTHER): •Fetal STAN monitor electrode inserted, but data masked to the caregivers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accommodative Relief for Uncomfortable Non-Presbyopes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Visual acuity of 20/25 or better in both eyes with habitual contact lenses~* -0.75 D or more myopic in both eyes~* -0.75 D or less astigmatism in both eyes~* Current single vision contact lens wearer who does not require a reading aid~* CLDEQ-8 score of 12 or more points with habitual contact lenses~* No history of ocular surgery or medication~* Reports digital device use of at least 3 hours per day~* No significant signs of dry eye (grade 1 or less ocular surface staining, Schirmer score of 7 mm or more, and tear break up time of 7 seconds or more in bother eyes)~* No significant binocular vision disorders in both eyes (eso or exophoria of 4 prism diopters or less at distance and near, near point of convergence of 6 mm or less, no history of strabismus or patching)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Single Vision First (Type: EXPERIMENTAL): Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
- Multifocal first (Type: EXPERIMENTAL): Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. M/F patients 18 years of age or older~2. Diagnosis of ESRD (GFR ≤ 15 mL/min)~3. CAPD or APD using only Dianeal and/or Physioneal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time~4. DM (Type 1 and 2) on glycemic-control medication, for 90 days~5. HbA1c \> 6.0% but ≤ 12.0%~6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL~Exclusion Criteria:~1. Cardiovascular event within the last 90 days~2. Ongoing clinically significant congestive heart failure (NYHA class III or IV)~3. Allergy to starch-based polymers~4. Glycogen storage disease~5. Glycogen storage disease~6. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days~7. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP \< 77) at Screening.~8. Serum urea \> 30 mmol/L~9. Receiving rosiglitazone maleate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- non glucose sparing (Type: ACTIVE_COMPARATOR): Dianeal only
- Glucose sparing (Type: EXPERIMENTAL): Physioneal, Extraneal, Nutrineal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable Peritoneal dialysis~* Stable Hemodialysis~* Age 18-85 years~Exclusion Criteria:~* use of hypnotics, MAO inhibitors or neuroleptics~* Liver disease~* Participation in drug investigation \< 1 months to start~* Former use of melatonin~* Severe neurological/psychiatric disease~* Allergic to melatonin or additives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete